Advertisement
UK markets closed
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • CRUDE OIL

    83.07
    +1.72 (+2.11%)
     
  • GOLD FUTURES

    2,240.20
    +27.50 (+1.24%)
     
  • DOW

    39,828.02
    +67.94 (+0.17%)
     
  • Bitcoin GBP

    56,161.14
    +1,854.24 (+3.41%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,390.32
    -9.20 (-0.06%)
     
  • UK FTSE All Share

    4,338.05
    +12.12 (+0.28%)
     

Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.